Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. (not Beyond Air, Inc.) on February 16, 2017, regarding events occurring on February 12, 2017. The company is a Delaware corporation headquartered in Rehovot, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Executive Departure: Ms. Racheli Vizman, the Chief Operating Officer (COO), submitted her resignation, effective March 20, 2017.
- Reason: Ms. Vizman resigned to pursue new opportunities.
- Disagreement: The filing explicitly states the resignation is not due to any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the standard disclosure of the officer's departure.
Investor Verification Checklist
- Confirm the appointment of a successor to the Chief Operating Officer role.
- Review the company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.
- Verify if the departure of the COO impacts ongoing clinical trials or operational milestones.